Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, People's Republic of China.
Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, Jiangsu, People's Republic of China.
Drug Des Devel Ther. 2021 Apr 7;15:1485-1493. doi: 10.2147/DDDT.S297642. eCollection 2021.
To evaluate the effectiveness and safety of lidocaine on postoperative quality of recovery and lung protection of patients undergoing thoracoscopic radical resection of lung cancer.
Seventy ASA II-III patients undergoing thoracoscopic radical resection of lung cancer were randomly assigned into either the lidocaine group (Group L) or control group (Group C). Patients in Group L received lidocaine with a 1.5 mg/kg bolus before induction of anesthesia, followed by 2.0 mg/kg/h until the end of the operation while the patients in Group C received volume-matched normal saline at the same rate. The main outcome was the quality of recovery-40 score (QoR-40 score) at 24 h postoperatively. The peak airway pressure (Ppeak) and plateau airway pressure (Pplat), the partial pressure of oxygen in arterial blood (PaO), partial pressure of carbon dioxide in arterial blood (PaCO), alveolar-arterial oxygen gradient (A-aDO2), oxygenation index (OI), time to first flatus and defecation, intraoperative hemodynamics and opioid consumption were also recorded.
There were no statistically difference at patients' baseline characteristics. The QoR-40 score of Group L was significantly higher than that of Group C at 24 h after surgery (=0.014). Ppeak, Pplat, and A-aDO of Group L were significantly lower than those of Group C (<0.001, <0.001, =0.025, respectively) after the ventilation recovery of both lungs, and the PaO and OI of the Group L were significantly higher than those of Group C (=0.027, =0.027, respectively). Time to first flatus and defecation in Group L was significantly lower compared with Group C (=0.037, =0.025, respectively).
Intravenous lidocaine can improve the quality of recovery of patients undergoing thoracoscopic radical resection of lung cancer, while also providing lung protection, favorable postoperative analgesia, a reduction in the time to first flatus and defecation after surgery.
评价利多卡因对行电视辅助胸腔镜肺癌根治术患者术后恢复质量和肺保护的有效性和安全性。
70 例美国麻醉医师协会(ASA)分级Ⅱ-Ⅲ级行电视辅助胸腔镜肺癌根治术的患者,随机分为利多卡因组(L 组)和对照组(C 组)。L 组患者在麻醉诱导前给予 1.5mg/kg 利多卡因负荷量,然后以 2.0mg/kg/h 的速度输注至手术结束,而 C 组患者以相同的速度给予等容量的生理盐水。主要结局是术后 24 小时的恢复质量-40 分(QoR-40 分)评分。记录术后两组患者的气道峰压(Ppeak)和平台压(Pplat)、动脉血氧分压(PaO)、动脉血二氧化碳分压(PaCO)、肺泡-动脉氧分压差(A-aDO2)、氧合指数(OI)、首次排气和排便时间、术中血流动力学和阿片类药物用量。
两组患者的基线特征无统计学差异。L 组患者术后 24 小时的 QoR-40 评分明显高于 C 组(=0.014)。两组患者双肺通气恢复后,L 组的 Ppeak、Pplat 和 A-aDO2 明显低于 C 组(<0.001,<0.001,=0.025),PaO 和 OI 明显高于 C 组(=0.027,=0.027)。L 组患者首次排气和排便时间明显短于 C 组(=0.037,=0.025)。
静脉注射利多卡因可改善行电视辅助胸腔镜肺癌根治术患者的术后恢复质量,同时提供肺保护、良好的术后镇痛、减少术后首次排气和排便时间。